LANDMARK TRADEMARK INJUNCTION IN PHARMACEUTICAL COUNTERFEITING

April 1, 2026

Nandini Sharma

National Law Institute University

Case Name: Aventis LLC v. Healing Pharma India Pvt Ltd & Ors.

Citation: Commercial IP Suit No. 139 of 2021, Bombay High Court

Court: Bombay High Court

Corum/Judges: Honourable Justice K.R. Shriram

Abstract

Besides being a business matter, pharmaceutical trademark disputes are about patient safety and building trust in medicines. The 2025 decision by the Bombay High Court in Aventis LLC v. Healing Pharma India Pvt. Ltd. pertains to a contempt petition arising out of repeated violation of an injunction protecting the antihistamine brand Allegra. The court found Healing Pharma guilty of willful disobedience when, after agreeing to stop using the deceptively similar mark “Allergegra”, it re-entered the market with another confusing mark, “Algreat”, with similar packaging. This judgment highlights that counterfeiting in medicines is a serious threat to public health, and disobedience of IP injunctions in such cases would face strict consequences, including high costs and possible civil imprisonment.

Introduction

Counterfeit medicines, linked to both intellectual property violations and threats to human life, make Aventis LLC v. Healing Pharma a crucial decision for both trademark law and public health, since it demonstrates how strictly the courts respond when their injunctions are flouted in pharma disputes.

The real-world context for this case is the Indian pharmaceutical market, with branded antihistamines such as Allegra coexisting with a multitude of generic and look-alike products, creating scope for confusion and abuse.

The plaintiff, Aventis LLC, part of the Sanofi group, is the proprietor of the well-known antihistamine brand Allegra, while the defendants, Healing Pharma India Pvt. Ltd. and associated entities, were engaged in manufacturing and selling competing allergy medicines. Aventis claimed that the defendants’ products under marks such as “Allergegra” and later “Algreat” copied the Allegra mark and trade dress so closely that they misled consumers.

The case was heard by the Bombay High Court, Commercial Division, Single Judge Bench, with the contempt order passed in 2025 in continuation of an earlier permanent injunction granted in 2021.

Facts

The dispute started in October 2020, when Aventis learned of infringing sales. Massive quantities of “Allergegra” products matching the strengths of Allegra, 30mg, 60mg, 120mg, and 180mg, were seized during raids.
Defendants used phonetically and visually similar marks: “Allergegra” imitated “Allegra” in font, colour, and layout.
Aventis obtained an ex-parte ad-interim relief dated 27 November 2020, restraining manufacture, sale, or distribution.
The court made the injunction permanent in March 2021. The defendants agreed to comply.
In 2022, Aventis found “Algreat” products with renovated but confusing packaging in violation of the order.
Contempt petition filed; 2025 hearing – evidence of willful disobedience shown.

These facts follow a pattern: initial infringement, court order, superficial compliance, followed by a re-offence with a changed mark.

Issues

Did the defendants commit willful contempt by using “Algreat” despite the 2021 injunction against similar marks to Allegra?
Does counterfeiting antihistamines involve a public health risk beyond trademark harm that would justify exemplary penalties?
What remedies, such as imprisonment or destruction of goods, best enforce IP orders in pharma cases?
The pivotal question was whether “Algreat” fell outside the scope of the injunction, which proscribed “deceptively similar” marks and packaging.

Reasoning

The reasoning in the decision of Aventis LLC v. Healing Pharma is strong because it declines to view this as a “technical” violation and instead reads the defendant’s actions as a narrative of willful disobedience. The change from “Allergegra” to “Algreat” is not considered in isolation but against the backdrop of a permanent injunction, which clearly barred any mark or trade dress deceptively similar to Allegra.

Emphasising phonetic proximity, similar get-up, and the same therapeutic segment, what the court says is that once you are enjoined, you do not get to play word games around the brand and pretend compliance. This reinforces the notion that injunctions in IP are obligations of conduct and not drafting puzzles for creative infringers.

Another important aspect is how the court connects contempt with public health rather than merely IP enforcement. The reasoning appears to indicate that in the pharmaceutical context, confusion is not a mere commercial inconvenience, but can translate into wrong drugs, wrong dosages, or substandard quality reaching patients.

The move to impose high costs and to keep civil imprisonment on the table reflects a conscious choice to make contempt in pharma IP “painful enough” to deter repeat behaviour. Doctrinally, the judgment quietly extends the practical bite of Sections 29 and 135 of the Trademarks Act by using contempt authority: once a permanent injunction is in place, testing its limits becomes an extremely costly affair for the infringer.

A more subtle but interesting element is how the court reads intention from conduct. The defendants never say, “we intended to copy”, but their pattern of copy, consent to the injunction, and re-enter with a slightly tweaked mark allows the court to infer bad faith.

This is important because, in many pharma disputes, defendants argue they have “rebranded” in good faith.

It pushes the parties towards genuinely distinct branding rather than incremental imitation.

Critique

According to me, the decision is normatively appealing, but it does leave some doctrinal gaps open, which may be relevant for future litigation.

First, while the result in favour of Aventis seems supportable on these facts, the court does not take much time to articulate a clear test for when a “post-injunction” rebrand will be considered contemptuous.

In a system dominated by generics, there will be cases where parties genuinely try to move away from a prohibited mark but remain in the same therapeutic space.

A more structured framework combining.

degree of similarity
timing
internal documents/intent
market behavior

would have given lower courts better guidance and also provided comfort to honest generic manufacturers.

The judgment also leans heavily into the public health argument, which is intuitively persuasive, but it does not fully engage the tricky question of when strict IP enforcement in medicines stops protecting patients and starts limiting access. There is, after all, a thin line between punishing counterfeiting and chilling competition in a country where legitimate generics are often the only affordable option.

The court is clearly on the right side in this case because the facts point to bad faith. Still, a brief acknowledgement that contempt is being used against deliberate imitation, not against generics per se, would have helped demarcate the boundary more clearly.

Without that nuance, there is a risk that rights-holders may over-read the judgment as a general license to pursue contempt for any close branding in the pharma space.

Finally, from an academic point of view, the case is interesting because it silently repositions contempt as the central enforcement tool in Indian IP practice, particularly for pharmaceuticals. I believe that this is both an opportunity and a warning: an opportunity because it allows courts to respond quickly and meaningfully to repeat violators and a warning. After all, contempt, if overused or applied to borderline cases, could become a blunt instrument that stifles legitimate competition.

The actual contribution of Aventis v. Healing Pharma would depend on how carefully future courts distinguish between deliberate “Allegra–Allergegra–Algreat” type conduct and close but good-faith branding choices in a crowded therapeutic market.

Impact

On IP Enforcement: This sends a strong signal that disobedience of trademark injunctions, particularly in pharmaceuticals, will invite strong contempt action. It fortifies the practical utility of injunctions as an enforcement mechanism and not a paper order only.

On pharmaceutical branding: Companies with “close mimic” branding for now face greater risks because courts are more willing to look at overall trade dress, phonetic similarity, and conduct after an injunction and not solely the literal text of such an order. This may encourage more distinctive branding in generics.

On public health: The judgment promotes patient-centeredness in IP law by highlighting the health dangers caused by confusing medicine brands. It aligns trademark protection with consumer protection and does not treat them as separate silos.

This decision is a strong example of contempt, pharmaceutical trademark injunctions, and the intersection of IP enforcement with public health policy.

Conclusion

Aventis LLC v. Healing Pharma is an important Bombay High Court trademark injunction case that turns a standard infringement dispute into a powerful statement on contempt and public health.

By penalising repeat violations and emphasising the seriousness of counterfeiting in medicines, the court reinforces that its orders in pharma IP disputes are to be strictly followed and not strategically sidestepped. The judgment consolidates the use of contempt authority within trademark law but does not address the bigger questions about striking a balance between brand protection and access to medicines in India’s generics-heavy market.

References